RecruitingPregnancyPreeclampsia (PE)
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
Eligible age
18–45 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
Sponsor: University of Mississippi Medical Center
You may qualify if…
- ✓ UMMC antepartum patients with preterm PE between 23 0/7ths and 34 0/7ths weeks gestation when initially evaluated
- ✓ Willing and able to understand study procedures and to provide informed consent
You may not qualify if…
- ✕ \>33 weeks gestational age or \<23 weeks gestation
- ✕ Maternal compromise requiring emergent delivery (ongoing placental abruption, DIC, pulmonary edema).
- ✕ Fetal compromise requiring emergent delivery (fetal bradycardia, recurrent late fetal heart rate decelerations, minimal to absent fetal heart rate variability).
- ✕ Parameters according to current practice guidelines that exclude a patient from expectant management include the following:
- ✕ Preterm premature rupture of membranes (PPROM) \> 34 weeks gestation;
- ✕ Platelet count \< 100,000/microliter (thrombocytopenia) with evidence of HELLP syndrome;
- ✕ Persistently abnormal hepatic enzyme concentrations (twice or more upper normal values);
- ✕ Severe fetal growth restriction (ultrasound-estimated fetal weight less than fifth percentile);
Where it's recruiting
Mississippi
Jackson
Source: ClinicalTrials.gov · NCT02989025 · last updated 2026-05-01